ChemMedChem · 2011 · 12 citations · 35 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryEnzyme InhibitionPharmacokinetics Of Anticancer DrugsIntraperitoneal AdministrationIntraperitoneal BioavailabilityMatrix Metalloproteinase InhibitorsMurine ModelsOral Drug Bioavailability
Seven 4-phenoxybenzenesulfonamidopolymethylene carbamoylphosphonates (CPOs) bearing two to eight methylene units in the polymethylene chain were synthesized and evaluated as matrix metalloproteinase (MMP) inhibitors. The five lowest homologues [(CH₂)₂-₆] are selective MMP-2 inhibitors, whereas the two with the longest linkers [(CH₂)₇,₈] lack inhibitory activity. The most potent homologues are those with (CH₂)₅,₆; these two were evaluated for antimetastatic activity in a murine melanoma model and showed good potency both by oral and intraperitoneal administration without any toxic--including musculoskeletal--side effects. In contrast to the previously reported cis-ACCP, which was shown to inhibit MMP-2 for ∼30 min, the new compounds inhibit MMP activity for the duration of measurement, lasting several hours. Pharmacokinetic evaluation revealed, on the one hand, low oral bioavailability; on the other hand, a relatively large calculated volume of distribution, consistent with the observed reversible absorption of CPO 5 to hydroxyapatite, as a model for bone.
35
Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats
Anne M. Romanic, Raymond F. White, Anthony J. Arleth et al. · Stroke · 1998 · 735 citations
Reuven Reich, Erik W. Thompson, Yasuhiko Iwamoto et al. · QUT ePrints (Queensland University of Technology) · 1988 · 354 citations
Medicine, Cell Biology, Oncology +17
Structure-activity relationships of various bisphosphonates
Hisashi Shinoda, G. Adamek, R. Felix et al. · Calcified Tissue International · 1983 · 307 citations
Pharmacy, Chemistry, Pharmacology +14